Drug Trial Radar · NCT06256588
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
864
Planned (sponsor's estimate)
Start
Mar 21, 2024
Primary completion
Jun 30, 2028
Study completion Oct 26, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
- Neoplasms, Head and Neck
Interventions
DostarlimabDrug
Dostarlimab will be administered as an intravenous (IV) infusion
PlaceboDrug
Placebo will be administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 5 years
Locations
277 sites in 31 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Jonesboro, Arkansas · Recruiting
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
Solvang, California · Recruiting
GSK Investigational Site
Stockton, California · Recruiting
GSK Investigational Site
Torrance, California · Recruiting
GSK Investigational Site
Farmington, Connecticut · Recruiting
GSK Investigational Site
New Haven, Connecticut · Recruiting
GSK Investigational Site
Washington D.C., District of Columbia · Recruiting
GSK Investigational Site
St. Petersburg, Florida · Recruiting
GSK Investigational Site
Tamarac, Florida · Withdrawn
GSK Investigational Site
Atlanta, Georgia · Recruiting
GSK Investigational Site
Fort Wayne, Indiana · Recruiting
GSK Investigational Site
Iowa City, Iowa · Recruiting
GSK Investigational Site
Lexington, Kentucky · Recruiting
GSK Investigational Site
Columbia, Maryland · Recruiting
GSK Investigational Site
Worcester, Massachusetts · Recruiting
GSK Investigational Site
St Louis, Missouri · Recruiting
GSK Investigational Site
Omaha, Nebraska · Recruiting
GSK Investigational Site
New York, New York · Completed
GSK Investigational Site
The Bronx, New York · Recruiting
GSK Investigational Site
Canton, Ohio · Recruiting
GSK Investigational Site
Cincinnati, Ohio · Completed
GSK Investigational Site
Tulsa, Oklahoma · Recruiting
GSK Investigational Site
Philadelphia, Pennsylvania · Recruiting
GSK Investigational Site
Pittsburgh, Pennsylvania · Recruiting
GSK Investigational Site
Charleston, South Carolina · Recruiting
GSK Investigational Site
Greenville, South Carolina · Completed
GSK Investigational Site
Chattanooga, Tennessee · Recruiting
GSK Investigational Site
Germantown, Tennessee · Recruiting
GSK Investigational Site
Nashville, Tennessee · Recruiting
GSK Investigational Site
Dallas, Texas · Recruiting
GSK Investigational Site
Fort Worth, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
GSK Investigational Site
Fredericksburg, Virginia · Recruiting
GSK Investigational Site
Wytheville, Virginia · Recruiting
GSK Investigational Site
Tacoma, Washington · Withdrawn
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina · Recruiting
Showing 40 of 277 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.